|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Detailed phenotyping including tumor IHC and its correlation with comprehensive STK11 genotyping by full gene sequencing followed by large genomic rearrangement analysis was performed in an Indian PJS cohort.
|
30689838 |
2019 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
All coding exons and exon/intron boundaries of the LKB1 gene were analyzed by direct sequencing in 77 renal cell carcinoma (RCC) tumors and 62 matched noncancerous tissue samples.
|
25179843 |
2014 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
None of STK11 mutated tumors (n = 7) expressed PD-L1.
|
30885341 |
2019 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
If the STK11 gene is one of the mutational targets of microsatellite instability, its inactivation may be associated with tumor development in a small proportion of colorectal cancers.
|
10429655 |
1999 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Pathogenic variants in the LKB1 tumor suppressor gene (also known as STK11) are the major cause of PJS.
|
28185117 |
2017 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
We found a trend towards worse overall survival in patients with KRAS/LKB1 co-mutated tumors as compared to KRAS-mutated ones (hazard ratio: 2.02, 95% confidence interval: 0.94-4.35, p = 0.072).
|
30149143 |
2018 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
The tumour was excised and the STK11 gene deletion identified in both patient and father.
|
20310004 |
2010 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
The inactivation of Stk11 in 27% (6/22) of IPMNs versus 7% (4/56) of pancreatic adenocarcinomas suggests genetic disparities in the pathogenesis of these closely related neoplasms.
|
12861065 |
2003 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
No deletion of band 19p13.3 was detected; therefore, the patient was not at an increased risk of tumors from the Peutz-Jeghers syndrome associated with a deletion of the STK11 gene.
|
27894106 |
2016 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Our findings illustrate how tumor suppressor mutations can modulate the immune milieu of the tumor microenvironment, and they offer specific implications for addressing STK11/LKB1-mutated tumors with PD-1-targeting antibody therapies.
|
26833127 |
2016 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Intratumoral mDC density was high with low pathological tumor stage (P = 0.01) and low with STK11 mutation (P = 0.004).
|
27299180 |
2016 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
PJS is caused by germline mutations in the tumor suppressor gene LKB1.
|
15608654 |
2005 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Germline mutations in LKB1 have been reported to underlie familial Peutz-Jeghers syndrome (PJS) with intestinal hamartomatous polyps and an elevated risk of various neoplasms.
|
9887330 |
1999 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Differentially expressed novel alternatively spliced transcript variant of tumor suppressor Stk11 gene in mouse.
|
29777910 |
2018 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
One hundred and seven lung adenocarcinomas with more than 70% tumor have been analyzed for mutation of LKB1 as well as LKB1 large deletions detection by using multiplex ligation-dependent probe amplification analysis.
|
24419424 |
2014 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Notably, this is not the case for non-small-cell lung cancer, where nearly half of the tumors harbor somatic and homozygous inactivating mutations in LKB1.
|
17599048 |
2007 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
NGS showed that the medullary component of this tumor had a novel STK11 p.G270W mutation, which was not present in the mucinous component.
|
31243107 |
2019 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Remarkably, LKB1 alterations frequently occur simultaneously with inactivation at another important tumor suppressor gene, BRG1 (also called SMARCA4), which is also located on chromosome 19p.
|
21516316 |
2011 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
In nearly 50% of patients PJS is caused by germ line mutations in the STK11/LKB1 serine/threonine kinase gene, the only kinase gene currently known to act as a tumor suppressor.
|
12112668 |
2002 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Variants in STK11, a tumour suppressor gene, located on Chromosome 19, predispose to PJS.
|
28900777 |
2018 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Inactivating mutations of the tumor suppressor gene Liver Kinase B1 (<i>LKB1</i>) are frequently detected in non-small-cell lung cancer (NSCLC) and cervical carcinoma.
|
31781355 |
2019 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Moreover, the tumor showed loss of heterozygosity of the 19p marker near STK11 and somatic mutation of the p53 gene.
|
12051537 |
2002 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Germline mutations of the tumor suppressor gene LKB1/STK11 are responsible for the Peutz-Jeghers syndrome (PJS), an autosomal-dominant disorder characterized by mucocutaneous pigmentation, hamartomatous polyps, and an increased risk of associated malignancies.
|
17404884 |
2007 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
Mutations in the serine-threonine tumor-suppressor kinase LKB1 are responsible for Peutz-Jeghers syndrome, characterized by hamartomatous proliferation and an increased risk of developing cancer.
|
17575127 |
2007 |
|
Neoplasms
|
0.200 |
GeneticVariation
|
group |
BEFREE |
To evaluate whether somatic mutations of LKB1 contribute to the tumorigenesis of yet unstudied tumor types, we screened 14 cell lines and 129 tumor specimens from different cancers for a genetic defect in LKB1.
|
10079245 |
1999 |